RxDoctor Payments Data

Linda Simmons

Family · Wilmington, DENPI 1497087902

Payments from drug & device makers

$487in general payments, 2019–2025

Across 8 payments — averaging $60.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi-aventis U.S. LLC$128
  • Lilly USA, LLC$122
  • Tandem Diabetes Care, Inc.$97
  • Novo Nordisk$46
  • Boston Scientific$45
  • Abbott$24
  • plus $24 from 1 others

What the payments were for

  • Food & beverage$487100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$487 in reported general payments places this provider in the 45th percentile of 523 family providers in Delaware.

See all family providers in Delaware

Medicare billing

Part B allowed, 2024
$64,843
Medicare patients
376
Services billed
1,134

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide264$493,498
TrulicityDulaglutide177$326,607
JardianceEmpagliflozin239$268,070
MounjaroTirzepatide130$180,062
Tresiba Flextouch U-100Insulin Degludec85$86,304
JanuviaSitagliptin Phosphate62$70,162
FarxigaDapagliflozin Propanediol61$62,558
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog101$46,525
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/719$34,765
Novolog FlexpenInsulin Aspart100$31,362
Tresiba Flextouch U-200Insulin Degludec20$27,057
Janumet XrSitagliptin Phos/Metformin Hcl16$26,681
Lantus SolostarInsulin Glargine,hum.Rec.Anlog252$26,375
Humalog Kwikpen U-100Insulin Lispro71$20,466
Fiasp FlextouchInsulin Aspart (Niacinamide)20$20,198

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$122$506,669307 claims
Novo NordiskOzempic, Novolog, Novolog Mix 70-30$46$500,050287 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 523 family providers in Delaware.

Other family in Wilmington

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →